BioNTech Dirección

Dirección controles de criterios 4/4

El CEO de BioNTech es Ugur Sahin , nombrado en Jan 2008, tiene una permanencia de 16.83 años. compensación anual total es €3.06M, compuesta por 22.9% salario y 77.1% primas, incluidas acciones y opciones de la empresa. posee directamente un 17.23% de las acciones de la empresa, por valor de €4.02B. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 4.6 años, respectivamente.

Información clave

Ugur Sahin

Chief Executive Officer (CEO)

€3.1m

Compensación total

Porcentaje del salario del CEO	22.9%
Permanencia del CEO	16.8yrs
Participación del CEO	17.2%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	4.6yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Ugur Sahin en comparación con los beneficios de BioNTech?
Fecha	Compensación total	Salario	Ingresos de la empresa
Sep 30 2024	n/a	n/a	-€467m
Jun 30 2024	n/a	n/a	-€504m
Mar 31 2024	n/a	n/a	€113m
Dec 31 2023	€3m	€700k	€930m
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€4b
Mar 31 2023	n/a	n/a	€6b
Dec 31 2022	€6m	€360k	€9b
Sep 30 2022	n/a	n/a	€10b
Jun 30 2022	n/a	n/a	€12b
Mar 31 2022	n/a	n/a	€13b
Dec 31 2021	€12m	€360k	€10b
Sep 30 2021	n/a	n/a	€7b
Jun 30 2021	n/a	n/a	€4b
Mar 31 2021	n/a	n/a	€1b
Dec 31 2020	€17m	€360k	€15m
Sep 30 2020	n/a	n/a	-€410m
Jun 30 2020	n/a	n/a	-€230m
Mar 31 2020	n/a	n/a	-€192m
Dec 31 2019	€7m	€311k	-€179m
Sep 30 2019	n/a	n/a	-€122m
Jun 30 2019	n/a	n/a	-€116m
Mar 31 2019	n/a	n/a	-€77m
Dec 31 2018	€653k	€210k	-€48m

Compensación vs. Mercado: La compensación total ($USD3.20M) de Ugur está en línea con el promedio de empresas de tamaño similar en el mercado Austrian ($USD4.40M).

Compensación vs. Ingresos: La compensación de Ugur ha sido consistente con los resultados de la empresa en el último año.

CEO

Ugur Sahin (59 yo)

16.8yrs

Permanencia

€3,056,000

Compensación

Prof. Dr. Ugur Sahin, MD, is the Chief Executive Officer and Co-Founder of BioNTech SE since 2008 and serves as its Member of Management Board since 2008 and serves as its Chair of the Management Board. Pr...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ugur Sahin	Co-Founder	16.8yrs	€3.06m	17.23% € 4.0b
Ozlem Tureci	Co-Founder	6.8yrs	€814.00k	0.38% € 89.0m
Jens Holstein	CFO & Member of Management Board	3.3yrs	€1.32m	0.00068% € 158.9k
Sierk Poetting	MD, COO & Member of Management Board	10.8yrs	€821.00k	0.31% € 73.5m
Ryan Richardson	Chief Strategy Officer	4.8yrs	€1.41m	0.0061% € 1.4m
James Timothy Ryan	Chief Legal & Business Officer & Member of the Management Board	1.2yrs	€848.00k	sin datos
Sean Marett	Executive Officer	less than a year	€133.00k	0.34% € 79.4m
Lisa Birringer	Senior Vice President of Global Financial Reporting & Accounting	less than a year	sin datos	sin datos
Zach Taylor	Senior Vice President of Corporate Development & Strategy	less than a year	sin datos	sin datos
Katalin Kariko	Senior VP & External Consultant for RNA Protein Replacement Therapies	no data	sin datos	sin datos
Oliver Henning	Senior Vice President of Operations	no data	sin datos	sin datos
Sebastian Kreiter	Senior Vice President of Immunotherapy & Preclinical Research	no data	sin datos	sin datos

3.3yrs

Permanencia media

57yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de BNTX se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Rudolf Staudigl	Supervisory Board Member	2.4yrs	€90.00k	0.00017% € 39.7k
Ulrich Wandschneider	Independent Deputy Chairman Supervisory Board	6.8yrs	€114.00k	sin datos
Michael Motschmann	Independent Supervisory Board Member	16.8yrs	€80.00k	sin datos
Helmut Jeggle	Independent Supervisory Board Chairman	16.8yrs	€226.00k	0.14% € 32.4m
Nicola Blackwood	Member of Supervisory Board	1.5yrs	€46.00k	sin datos
Anja Morawietz	Supervisory Board Member	2.4yrs	€105.00k	0.00010% € 23.4k

4.6yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de BNTX se considera experimentada (4.6 años de antigüedad promedio).

BioNTech Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

BioNTech SE, Annual General Meeting, May 17, 2024

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Recent updates

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Biotheus Inc. for $950 million.

New major risk - Revenue and earnings growth

Third quarter 2024 earnings released: EPS: €0.82 (vs €0.67 in 3Q 2023)

BioNTech SE to Report Q3, 2024 Results on Nov 04, 2024

BioNTech and OncoC4 Announce U.S. Food and Drug Administration Placed A Partial Clinical Hold on the Two-Stage, Open-Label, Randomized Phase 3 Trial, PRESERVE-003 (NCT05671510)

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron KP.2-Adapted Covid-19 Vaccine in the European Union

New major risk - Revenue and earnings growth

New major risk - Share price stability

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval & Authorization for Omicron KP.2-Adapted COVID-19 Vaccine

Pfizer and BioNTech Provide Update on mRNA -Based Combination Vaccine Program Against Influenza and COVID-19 in Individuals 18-64 Years of Age

University of Pennsylvania Files A Lawsuit Against BioNTech SE and Biontech Rna Pharmaceuticals GmbH

Second quarter 2024 earnings released: €3.36 loss per share (vs €0.79 loss in 2Q 2023)

BioNTech SE Reiterates Earnings Guidance for the Year 2024

BioNTech SE to Report Q2, 2024 Results on Aug 05, 2024

New minor risk - Earnings quality

New major risk - Revenue and earnings growth

BioNTech SE Reiterates Revenue Guidance for the Full Year 2024

First quarter 2024 earnings released: €1.31 loss per share (vs €2.07 profit in 1Q 2023)

BioNTech SE to Report Q1, 2024 Results on May 06, 2024

New major risk - Revenue and earnings growth

New minor risk - Profit margin trend

Full year 2023 earnings released: EPS: €3.87 (vs €38.78 in FY 2022)

BioNTech SE Announces Appointment of Annemarie Hanekamp as Chief Commercial Officer, Effective July 1, 2024

BioNTech SE Announces Retirement of Sean Marett as Chief Business and Commercial Officer

New minor risk - Shareholder dilution

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Receives FDA Fast Track Designation for Next-Generation Antibody-Drug Conjugate Candidate BNT325 DB-1305

BioNTech SE and Duality Biologics (Suzhou) Co., Ltd. Initiate Pivotal Phase 3 Trial of Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Metastatic Breast Cancer

Robbins LLP Informs Investors of Class Action Filed Against BioNTech SE

BioNTech and Duality Biologics (Suzhou) Co. Ltd. Receive FDA Breakthrough Therapy Designation for Antibody-Drug Conjugate Candidate BNT323 DB-1303 in Endometrial Cancer

BioNTech SE (NasdaqGS:BNTX) agreed to acquire Aexerna Therapeutics.

Third quarter 2023 earnings released: EPS: €0.67 (vs €7.43 in 3Q 2022)

BioNTech SE to Report Q4, 2023 Results on Mar 20, 2024

Pfizer Inc. and BioNTech SE Announce Positive Topline Data for MRNA-Based Combination Vaccine Program Against Influenza and Covid-19

BioNTech SE, Annual General Meeting, May 17, 2024

Investor sentiment deteriorates as stock falls 16%

BioNTech SE Expands Late-Stage Clinical Oncology Portfolio with Initiation of Further Phase 2 Trial with mRNA-Based Individualized Neoantigen Specific Immunotherapy in New Cancer Indication

Curevac Reports Progress in Intellectual Property Infringement Case Against Biontech in Germany

Pfizer and Biontech Receive Health Canada Authorization for Xbb.1.5-Adapted Monovalent Covid-19 Vaccine

Pfizer Inc. and BioNTech SE Receive U.S. FDA Approval for 2023-2024 COVID-19 Vaccine

New major risk - Share price stability

Investor sentiment improves as stock rises 17%

BioNTech Appoints James Ryan as Chief Legal Officer Effective September 1, 2023

Second quarter 2023 earnings released: €0.79 loss per share (vs €6.86 profit in 2Q 2022)

BioNTech SE to Report Q3, 2023 Results on Nov 06, 2023

BioNTech SE acquired remaining stake in InstaDeep Ltd for approximately £430 million.

BioNTech SE to Report Q2, 2023 Results on Aug 07, 2023

BioNTech SE and OncoC4, Inc. Initiate Pivotal Phase 3 Trial of BNT316/ONC-392 Program in Metastatic NSCLC

New minor risk - Share price stability

BioNTech SE Provides Revenue Guidance for the Full Year 2023

Full year 2022 earnings released: EPS: €38.78 (vs €42.18 in FY 2021)

BioNTech SE Initiates Phase 1 Clinical Trial for Malaria Vaccine Program BNT165

BioNTech SE Starts Phase 1 Clinical Trial for Prophylactic Herpes Simplex Virus-2 Vaccine Candidate BNT163

Pfizer and BioNTech SE Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Children 5 Through <12 Years of Age

BioNTech SE and Pfizer Inc. Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-adapted bivalent COVID-19 Vaccine in Children Under 5 years

Pfizer and BioNTech Report New Data on Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Improved Immune Response Against Emerging Omicron Sublineages

Pfizer Inc. and BioNTech SE Advances Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T Cell Responses and Duration of Protection

Pfizer and Biontech Receive Positive Chmp Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union

Third quarter 2022 earnings released: EPS: €7.43 (vs €13.14 in 3Q 2021)

BioNTech SE Se Revises Its Earnings Guidance for the Full Year 2022

Pfizer Inc. and BioNTech SE Announces Updated Clinical Data for Omicron Ba.4/Ba.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine

Pfizer and Biontech Receive Positive CHMP Opinion for Comirnaty® in Children 6 Months to Less Than 5 Years in the European Union

Pfizer and BioNTech Announce Positive Early Data from Clinical Trial of Omicron BA.4/BA.5-Adapted Bivalent Booster in Individuals 18 Years and Older

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Canada ULC and BioNTech SE's Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster Receives Health Canada Authorization for Individuals 12 Years of Age and Older

Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent Vaccine Booster in Children 5 Through 11 Years of Age

Pfizer Inc. and BioNTech SE Receive Positive Chmp Opinion for Conversion of Comirnaty® Conditional Marketing Authorization to Full Marketing Authorization in the European Union

Pfizer and BioNTech SE Receive Positive CHMP Opinion for Omicron Ba.4/Ba.5-Adapted Bivalent Covid-19 Vaccine Booster in European Union

Biontech Presents Encouraging Phase 1/2 Follow-Up Data for Car-T Candidate Bnt211 in Hard-To-Treat Solid Tumors At ESMO

Pfizer Inc. and BioNTech SE Receive Positive CHMP Opinion for Omicron BA.1-Adapted Bivalent COVID-19 Vaccine Booster in European Union

Pfizer and BioNTech Granted FDA Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Ages 12 Years and Older